Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A Ramos,Natalie S Grover,Anne W Beaven,Premal D Lulla,Meng-Fen Wu,Anastasia Ivanova,Tao Wang,Thomas C Shea,Cliona M Rooney,Christopher Dittus,Steven I Park,Adrian P Gee,Paul W Eldridge,Kathryn L McKay,Birju Mehta,Catherine J Cheng,Faith B Buchanan,Bambi J Grilley,Kaitlin Morrison,Malcolm K Brenner,Jonathan S Serody,Gianpietro Dotti,Helen E Heslop,Barbara Savoldo,Carlos A. Ramos,Natalie S. Grover,Anne W. Beaven,Premal D. Lulla,Thomas C. Shea,Cliona M. Rooney,Steven I. Park,Adrian P. Gee,Paul W. Eldridge,Kathryn L. McKay,Catherine J. Cheng,Faith B. Buchanan,Bambi J. Grilley,Malcolm K. Brenner,Jonathan S. Serody,Helen E. Heslop
DOI: https://doi.org/10.1200/jco.20.01342
IF: 45.3
2020-11-10
Journal of Clinical Oncology
Abstract:PURPOSE Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS We conducted 2 parallel phase I/II studies (ClinicalTrials.gov identifiers: NCT02690545 and NCT02917083 ) at 2 independent centers involving patients with relapsed or refractory HL and administered CD30.CAR-Ts after lymphodepletion with either bendamustine alone, bendamustine and fludarabine, or cyclophosphamide and fludarabine. The primary end point was safety. RESULTS Forty-one patients received CD30.CAR-Ts. Treated patients had a median of 7 prior lines of therapy (range, 2-23), including brentuximab vedotin, checkpoint inhibitors, and autologous or allogeneic stem cell transplantation. The most common toxicities were grade 3 or higher hematologic adverse events. Cytokine release syndrome was observed in 10 patients, all of which were grade 1. No neurologic toxicity was observed. The overall response rate in the 32 patients with active disease who received fludarabine-based lymphodepletion was 72%, including 19 patients (59%) with complete response. With a median follow-up of 533 days, the 1-year progression-free survival and overall survival for all evaluable patients were 36% (95% CI, 21% to 51%) and 94% (95% CI, 79% to 99%), respectively. CAR-T cell expansion in vivo was cell dose dependent. CONCLUSION Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30.CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.
oncology